E
Eugene Braunwald
Researcher at Brigham and Women's Hospital
Publications - 1758
Citations - 278949
Eugene Braunwald is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Myocardial infarction & TIMI. The author has an hindex of 230, co-authored 1711 publications receiving 264576 citations. Previous affiliations of Eugene Braunwald include Boston University & University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
A second look at bivalirudin.
TL;DR: The bivalirudin story has not ended because of a new sponsor and a second look under-taken by several groups of investigators, but there was a trend toward a reduction in favor of the drug and a decision to terminate further clinical studies with bivalIRudin.
Journal ArticleDOI
Opposing Effects of β Blockers and Angiotensin-Converting Enzyme Inhibitors on Development of New-Onset Diabetes Mellitus in Patients With Stable Coronary Artery Disease
Orly Vardeny,Hajime Uno,Eugene Braunwald,Jean L. Rouleau,Bernard J. Gersh,Aldo P. Maggioni,Michael J. Domanski,Marc A. Pfeffer,Scott D. Solomon +8 more
TL;DR: It is suggested that ACE inhibition may attenuate the risk for glucose abnormalities observed in patients taking β blockers, and this risk was decreased in patients treated concurrently with an ACE inhibitor.
Journal Article
Electroaugmentation of human and cat papillary muscle produced by paired electrical stimulation.
Journal ArticleDOI
Edoxaban in atrial fibrillation patients with established coronary artery disease: Insights from ENGAGE AF-TIMI 48.
Thomas A Zelniker,Christian T. Ruff,Stephen D. Wiviott,Jean-Jacques Blanc,Riccardo Cappato,Francesco Nordio,Michele Mercuri,Hans Lanz,Elliott M. Antman,Eugene Braunwald,Robert P. Giugliano +10 more
TL;DR: The reduction in ischemic events with the higher-dose edoxaban regimen versus warfarin was greater in patients with CAD, while bleeding was significantly reduced with edoxaba regardless of CAD status.
Journal ArticleDOI
Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials: Insights From the TIMI trials.
Emily S. Lau,Eugene Braunwald,Eugene Braunwald,David A. Morrow,David A. Morrow,Robert P. Giugliano,Robert P. Giugliano,Elliott M. Antman,Elliott M. Antman,C. Michael Gibson,Benjamin M. Scirica,Benjamin M. Scirica,Erin A. Bohula,Erin A. Bohula,Stephen D. Wiviott,Stephen D. Wiviott,Deepak L. Bhatt,Deepak L. Bhatt,Marc P. Bonaca,Christopher P. Cannon,Christopher P. Cannon,KyungAh Im,KyungAh Im,Jianping Guo,Jianping Guo,Marc S. Sabatine,Marc S. Sabatine,Michelle L. O'Donoghue,Michelle L. O'Donoghue +28 more
TL;DR: In this article, women are more likely than men to prematurely discontinue study drug or withdraw consent once enrolled in a clinical trial, and women are underrepresented across cardiovascular clinical trials.